Citron Pharma Launches Rosuvastatin Calcium Tablets

Shipments Immediately Follow FDA Approval

EAST BRUNSWICK, N.J.--()--Citron Pharma LLC, a rapidly growing, US based, generic pharmaceutical company confirmed that on Tuesday, July 19, its licensing partner received final approval from the U.S. Food and Drug Administration (FDA) for their Abbreviated New Drug Application (ANDA) for Rosuvastatin Calcium 5, 10, 20 and 40 mg tablets, the generic version of AstraZeneca's CRESTOR® (rosuvastatin calcium) tablets. Following FDA approval, Citron Pharma immediately commenced shipments of the generic version of CRESTOR® to its customers in the U.S.

“Our customers expect this to be the largest generic launch in 2016. Citron responded by ensuring the highest level of customer service on initial shipments and stocking inventory.”

Ashok Mayya, Chief Operating Officer, noted, “Our team was on high alert preparing initial stocking quantities for launch to ensure the product could be shipped immediately following approval. The team did a remarkable job responding to the needs of our customers with a flawless launch. We’re on track to support 100% service levels for the product.”

Karen Strelau, Executive Vice President, Sales & Marketing, added, "Our customers expect this to be the largest generic launch in 2016. Citron responded by ensuring the highest level of customer service on initial shipments and stocking inventory.”

CRESTOR® had U.S. sales of approximately $6.7 billion for the 12 months ending May 31, 2016, according to IMS Health.

CRESTOR® is a licensed trademark of AstraZeneca.

About Citron Pharma

Citron Pharma is a privately held pharmaceutical company focused on developing and marketing generic products across diverse therapy segments. Since launching commercial operations in December 2013, Citron Pharma has launched 45 product families to date representing over 195 SKUs. The company remains focused on developing and marketing a broad portfolio of generic products comprising 31 approved new products to be launched in the next 12-24 months and 33 products currently in our development pipeline. Citron Pharma is committed to providing nationwide availability of high-quality generic products through a robust sales, marketing & distribution infrastructure, headquartered in East Brunswick, New Jersey.

Additional information is available on the company's website at www.citronpharma.com

Contacts

Citron Pharma
Business Development
Mr. Ira Baeringer, 732-917-6069
Executive Vice President
Email: ibaeringer@citronpharma.com
or
Customer Service
855-5-CITRON (855-524-8766)
Email: cs@citronpharma.com
Fax: 732-227-0203
Hours: 9:00am-8:00pm, EST Monday - Friday